Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE